USPTO Patent Application for WNT-Related Cancer Vaccines
Summary
The USPTO has published a patent application (US20260083831A1) filed by Geneos Therapeutics, Inc. The application details compositions and methods for treating WNT-related cancers using nucleic acid sequences encoding tumor-specific antigens, potentially in combination with checkpoint inhibitors.
What changed
The United States Patent and Trademark Office (USPTO) has published patent application US20260083831A1, filed on May 10, 2023, by Geneos Therapeutics, Inc. The application describes novel compositions comprising nucleic acid sequences encoding tumor-specific antigens associated with the WNT pathway, and methods for treating cancer using these compositions, potentially alongside checkpoint inhibitors.
This publication represents a new patent filing and does not impose immediate regulatory obligations. However, it signals potential future developments in cancer therapeutics. Companies operating in the pharmaceutical and biotechnology sectors, particularly those involved in vaccine development or oncology, should be aware of this filing as it may impact future research, development, and intellectual property landscapes.
Archived snapshot
Mar 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
VACCINES AND METHODS OF USING THE SAME TO TREAT WNT-RELATED CANCER
Application US20260083831A1 Kind: A1 Mar 26, 2026
Assignee
GENEOS THERAPEUTICS, INC.
Inventors
Alfredo PERALES-PUCHALT, Niranjan SARDESAI
Abstract
The present disclosure provides a composition comprising a nucleic acid sequence encoding from about 1 to about 100 amino acid sequences that are tumor-specific antigens, wherein at least one tumor-specific antigen is an amino acid sequence associated with a WNT pathway. In some embodiments, the nucleic acid sequence encodes from about 20 to about 60 tumor-specific antigens; wherein from about 1 to about 8 tumor-specific antigens are chosen from one or a combination of: WNT, CTNNB1, AXIN1, AXIN2, APC, CK1, and GSK3B. Also provided is a cell comprising any one or plurality of compositions disclosed herein. Also provided is a pharmaceutical composition comprising: (i) a therapeutically effective amount of one or a plurality of compositions as disclosed herein; and (ii) a pharmaceutically acceptable carrier. Also provided is a method of treating cancer in a subject in need thereof comprising administering to the subject: (i) a pharmaceutical composition comprising a nucleic acid sequence encoding about twenty or more neoantigens or epitopes specific for neoantigens; or (ii) a pharmaceutical composition disclosed herein. In some embodiments, the method further comprises administering to the subject a therapeutically effective amount of a checkpoint inhibitor.
CPC Classifications
A61K 39/0011 A61K 38/208 A61K 39/39558 A61P 35/00 A61K 2039/505 A61K 2039/53
Filing Date
2023-05-10
Application No.
18865104
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.